In this trial of 4038 diabetic patients with chronic kidney disease (not on dialysis) and anemia, patients were randomized to darbepoetin or placebo for a Hb goal of 13 g/dL (with rescue darbepoetin if Hb fell to 9 g/dL in the placebo group). There was no difference between the groups in the primary endpoints (death / cardiovascular event, or death / end stage renal disease), but the darbepoetin group had a higher rate of stroke (hazard ratio 1.92, CI 1.38-2.68). Risks of darbepoetin outweigh the benefits in this patient population (abstract)
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment